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Increased Iron Sequestration in Alveolar Macrophages in
Chronic Obtructive Pulmonary Disease
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Abstract
Free iron in lung can cause the generation of reactive oxygen species, an important factor in chronic obstructive pulmonary
disease (COPD) pathogenesis. Iron accumulation has been implicated in oxidative stress in other diseases, such as
Alzheimer’s and Parkinson’s diseases, but little is known about iron accumulation in COPD. We sought to determine if iron
content and the expression of iron transport and/or storage genes in lung differ between controls and COPD subjects, and
whether changes in these correlate with airway obstruction. Explanted lung tissue was obtained from transplant donors,
GOLD 2–3 COPD subjects, and GOLD 4 lung transplant recipients, and bronchoalveolar lavage (BAL) cells were obtained
from non-smokers, healthy smokers, and GOLD 1–3 COPD subjects. Iron-positive cells were quantified histologically, and the
expression of iron uptake (transferrin and transferrin receptor), storage (ferritin) and export (ferroportin) genes was
examined by real-time RT-PCR assay. Percentage of iron-positive cells and expression levels of iron metabolism genes were
examined for correlations with airflow limitation indices (forced expiratory volume in the first second (FEV1) and the ratio
between FEV1 and forced vital capacity (FEV1/FVC)). The alveolar macrophage was identified as the predominant ironpositive cell type in lung tissues. Futhermore, the quantity of iron deposit and the percentage of iron positive macrophages
were increased with COPD and emphysema severity. The mRNA expression of iron uptake and storage genes transferrin and
ferritin were significantly increased in GOLD 4 COPD lungs compared to donors (6.9 and 3.22 fold increase, respectively). In
BAL cells, the mRNA expression of transferrin, transferrin receptor and ferritin correlated with airway obstruction. These
results support activation of an iron sequestration mechanism by alveolar macrophages in COPD, which we postulate is a
protective mechanism against iron induced oxidative stress.
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produced by inflammatory cells has been strongly implicated in
the pathogenesis of COPD. In addition, excess iron accumulation
in the lung has been reported in association with cigarette smoke
[4–6] and severe emphysema [7]. Moreover, cigarette smoke can
alter lung iron metabolism in animal models [8]. However, it is
unknown where iron accumulates in lungs of COPD subjects, if
expression of iron uptake and storage genes in the lung differs
between controls and subjects with COPD, and whether changes
in iron metabolism correlate with disease severity.
This study sought to 1) quantify the iron deposits in the lung
tissue of lung transplant donors, GOLD 2–3 (moderate to severe
COPD), and GOLD 4 (very severe COPD) subjects, and in
bronchoalveolar lavage (BAL) cells from smokers, non-smokers,
and GOLD 1–3 COPD subjects, 2) identify the iron-accumulating
cell types in the lung parenchyma, 3) determine the expression of
transferrin and transferrin receptor (iron uptake), ferritin (iron
storage) and ferroportin (iron export), and 4) determine correla-

Introduction
Iron is critical for the maintenance of cell homeostasis, having
important roles in respiration, DNA synthesis, energy production,
and metabolism. However, excess iron can be detrimental because
of its potential to generate harmful free radicals. Because of this,
tight regulation of iron metabolism is essential. Perturbation from
normal physiologic iron concentrations has been associated with
the pathogenesis of aging, neurodegenerative disease,and cancer
[1,2], presumably via the generation of excess reactive oxygen
species (ROS). The role of iron in other diseases in which oxidative
stress has been implicated remains to be determined.
Chronic obstructive pulmonary disease (COPD), comprised of
irreversible airways obstruction and alveolar space enlargement or
emphysema, is a major cause of mortality and morbidity
worldwide [3]. Cigarette smoke is the main etiological factor of
COPD [3], which triggers an inflammatory response in the lung.
Oxidative stress induced by the free radicals in tobacco smoke and
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determined on Perls-DAB-CD68 co-stained slides from 3
randomly selected 10x fields containing $10 macrophages per
field.

tions of changes in iron metabolism gene expression with airflow
limitation indices (forced expiratory volume in the first second
(FEV1) and the ratio between FEV1 and forced vital capacity
(FEV1/FVC)) which are indicative of COPD severity.

RNA Isolation and Quantitative Real-time RT-PCR
Materials and Methods

Total RNA was isolated from human donor and GOLD 4
COPD lung tissue samples, and BAL cells using TRIzol reagent
(Invitrogen, Carlsbad, CA). Quantitative Real-Time RT-PCR was
performed as follow: the cDNA was synthesized using SuperScript
II reverse transcriptase (Invitrogen). Real-time RT-PCR employed
the Fast SYBR Green Master Mix (Applied Biosystems, Foster
City, CA) and gene-specific primers (Table S1) on an EcoTM RealTime PCR System (Illumina, San Diego, CA).Results were
standardized using the delta-delta CT method [13] using the
average of the expression GAPDH, HRPT1 (Hypoxanthine
phosphoribosyltransferase-1) and PPIA (Peptidylprolyl isomerase1) for normalization [14,15].

Ethics Statement
The lung parenchyma study was approved by the Human
Studies Committee of Washington University and the bronchoalveolar lavage study was approved by the Institutional Review
Board of the University Hospital of Reims.

Subjects, Lung Processing, Sampling, and Collection of
BAL
Lung samples were obtained from 20 GOLD 4 COPD subjects
receiving lung transplant, 9 GOLD 2–3 COPD subjects undergoing resection of lung cancer (avoiding areas affected by tumor),
and 8 non-COPD lung donors obtained following size adjustment
for transplantation as controls. The lungs were processed as
previously described [9]. BAL samples were obtained from a
second set of non-cancer, GOLD 1–3 COPD subjects, healthy
smokers and healthy non smokers who underwent fiberoptic
bronchoscopy according to American Thoracic Society recommendations [10–12]. Briefly, BAL was performed by instilling
saline solution in a sub-segmental bronchus, followed by aspiration
and discarding of the first 50 ml aliquot. The remaining BAL fluid
was centrifuged and cells were used for this study. In both subject
sets, COPD diagnosis and GOLD classification was based on
spirometric pulmonary function tests according to the Global
Initiative for Chronic Obstructive Lung Disease consensus
statement[3], and informed, written consent was obtained from
each subject.

Morphological Analysis
For 14 GOLD 4 COPD and 4 non-COPD subjects, CT-scan of
the frozen lungs was performed, and analyzed as previously
described [9]. Briefly, the mean radiograph attenuation, expressed
in Hounsfield Units (HU), was determined in the CT section
corresponding to the lung area of the tissue samples using a
separate image processing program (ImageJ; available at: http://
rsb.info.nih. gov/ij).

Statistical Analysis
A Student’s t test was used to compare between two groups, an
Anova analysis with a Tukey-Kramer post-hoc test was used to
compare between more than two groups and Spearman rank
correlation was used to test for correlations between variables with
a p#0.05 considered significant.Statistical analysis was performed
using Excel 2011 (Microsoft Corporation, Redmond, WA).

Histochemical Staining
Ferric iron was detected on serial 5-mm paraformaldehydefixed, paraffin-embedded lung sections using Perls DAB staining.
Briefly, slides were incubated for 30 min in 5% potassium
ferrocyanide (Sigma-Aldrich, St. Louis, MO) and 5% hydrochloric
acid, followed by a 15 min incubation in DAB (Peroxidase
Substrate Kit; Vector Laboratories, Burlingame, CA). Negative
control slides were incubated for 30 min in PBS and 15 min in
DAB. Immunohistochemical staining for macrophages, transferrin
or ferritin was performed using a Vectastain kit (Vector
Laboratories; Burlingame, CA) using mouse anti-CD68 (1:100,
KP1; Dako, Kyoto, Japan), rabbit anti-transferrin (1:30 000, A0061; DakoCytomation, Carpinteria, CA), or anti-H-ferritin
(1:2000, F-5012; Sigma) antibodies, respectively. Isotype-matched,
nonimmune immunoglobulins served as negative controls.

Results
Patient Characteristics
Peripheral lung tissue was obtained from 20 GOLD 4 COPD
subjects receiving lung transplants for severe emphysema (GOLD
4), 9 GOLD 2–3 COPD subjects undergoing resection of lung
cancer (avoiding areas affected by tumor), and 8 non-COPD
donor lungs as controls. Their clinical and demographic characteristics are displayed in Table 1. As expected, the donor group
consisted of younger, non-smokerssubjects. Pulmonary function
tests were not obtained from donors.
In addition to lung tissue samples, BAL cells were obtained from
another set of subjects: 8 healthy non-smokers, 8 healthy smokers,
and 10 GOLD 1–3 COPD subjects. Their clinical and
demographic information are presented in Table 2. As expected,
subjects with COPD had increased airflow limitation compared to
the healthy non-smokers and the healthy smokers groups. The
BAL differentials are also presented in Table 2. The total number
of inflammatory cells in the BAL fluid of smokers and COPD
subjects were higher than non-smokers. However, in each group
the predominant cell type (almost 90%) in the BAL were
macrophages.

Quantification and Identification of Iron-positive Cells
Lung sections were stained with Perls-DAB for iron content
(brown-black color) and anti-CD68 (red color) to identify
macrophages. Dark staining anthracotic material and macrophages with dark-colored content were assessed on a consecutive serial
section stained with nuclear fast red only (American Master Tech
Scientific Inc., St. Lodi, CA). Slides were scanned using a
NanoZoomer 2.0 (Hamamatsu Photonics, K.K., Japan) and the
staining was quantified using Image-Pro Plus Software (MediaCybernetics, Silver Spring, MD). The area of cells positive for iron
was calculated using the following formula: Iron positive cell area =
(Area of brown-black color on Perls-DABstained slide – Area of brown-black
color on the nuclear fast red slide)/(Area of pink color on the nuclear fast red
slide) x 100. The percentage of iron-positive macrophages was
PLOS ONE | www.plosone.org

Increased Iron Deposition in Severe COPD Lungs
Iron accumulation in the lung was examined in 20 GOLD 4
COPD, 9 GOLD 2–3 COPD, and 8 non-COPD lungs by PerlsDAB staining. To distinguish between iron deposits and other dark
anthracotic material, consecutive serial sections were stained with
nuclear fast red only. To quantify the iron deposits, we calculated
2
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Table 1. Clinical characteristics of subjects included in lung parenchyma study.

Characteristic

Donor

GOLD 2–3 COPD

GOLD 4 COPD

No. of subjects

8

9

20

Age

42618

62611*

5966*

Sex, M/F

4/3 (7/8)

4/5

7/14

Smoking Pack-years

060

41631

55627

FEV1 (% of predicted)

-

62617

1864#

FEV1:FVC

-

57615

3169#

BMI (kg/m2)

-

2865

2363#

*p,0.05 between donor and spirometric GOLD 2–3 or GOLD 4 COPD,
#
p,0.05 between spirometric GOLD 2–3 and GOLD 4 COPD.
doi:10.1371/journal.pone.0096285.t001

associated with COPD and emphysema severity, with an increase
in lung iron content in GOLD 4 COPD relative to GOLD 2–3
COPD subjects despite similar smoking pack years.

the iron-positive cell area by taking the area of brown-black color
on Perls-DAB stained slide minus the area of brown-black color on
the nuclear fast red stained slide divided by the area of pink color
on the nuclear fast red slide. Iron deposits were rarely found in
non-COPD lung parenchyma (Fig. 1A) but were detectable in the
parenchyma of GOLD 2–3 COPD lungs and appeared abundant
in GOLD 4 COPD lungs (Fig. 1B and 1C, respectively). The iron
positive cell area was significantly increased in severe GOLD 4
COPD lungs (23616%) compared to non-COPD (1.161.5%,
p = 1.961025) or GOLD 2–3 COPD (1.661.5%, p = 1.961025)
lungs (Fig. 1D). Moreover, iron positive cell area was found to
correlate with the mean radiograph attenuation at the level of the
lung tissue sample which is an index of emphysema severity
(Fig. 1E). Our data suggest that excess iron accumulation is also

Iron is Localized in Macrophages in COPD Lungs
To quantify the prevalence of iron-positive macrophages, we
performed co-staining of Perls-DAB and CD68 in lung sections. As
shown in Figure 2B/B’ and 2C/C’, iron co-localized with
macrophages in GOLD 2–3 and GOLD 4 COPD lungs,
respectively, but not in non-COPD lungs (Fig. 2A/A’). The
percentage of iron-positive macrophages was increased in GOLD
2–3 COPD lungs (26% 619, p = 6.1610212) and GOLD 4
COPD lungs (68616%, p = 6.1610212) compared to non-COPD
lungs (3.562.8%). Interestingly, the persentage of iron-positive

Table 2. Clinical characteristics of subjects included in BAL study.

Characteristic

Non Smokers

Smokers

GOLD 1–3 COPD

No. of subjects

8

8

10

Age

54615

45611

5767

Sex, M/F

5/3

4/4

8/2

Smoking Pack-years

060

39616*

45613*

FEV1 (% of predicted)

96613

8765

65616#

FEV1/FVC (%)

8166

7869

6269#

2763

27610

2665

1/8

0/8

5/10

2

BMI (kg/m )
Treatments (% of patient using the treatment):
Inhaled LABA
Inhaled SABA

0/8

0/8

1/10

Inhaled LAMA

0/8

0/8

3/10

Inhaled CS

1/8

0/8

4/10

Oral CS

0/8

0/8

1/10

Macrophages (%)

8766

8669

9065

Lymphocytes (%)

1066

766

663

Neutrophils (%)

262

768

464

Eosinophils (%)

162

060

061

Total cell number per ml

177 571

412 875

237 000

Cellular content of BAL

*p,0.05 between smokers or COPD and non smokers,
p,0.05 between non smokers or smokers and COPD, LABA = Long-Acting b-Agonists, SABA: Short-Acting b-Agonists., LAMA: Loan-acting muscarinic antagonists, CS:
corticosteroids.
doi:10.1371/journal.pone.0096285.t002

#
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Figure 2. Iron is localized in macrophages in lung of COPD
subjects and the percentage of iron positive macrophage
increases with severity of disease. Perls-DAB and CD68 costaining
was performed in lung samples obtained from (A–A’) a patient without
COPD, (B–B’) a patient with grade 2 COPD and (C–C’) a patient with
grade 4 COPD. (D) Percentage of iron positive macrophages was
assessed in 8 lungs from subjects without COPD, 9 lungs from subjects
with GOLD 2 or 3 COPD and lungs from 20 subjects with GOLD 4 COPD.
(E) Correlation between the percentage of iron positive macrophages
and the mean radiograph attenuation in the same lung area. *p,0.05
(Anova analysis with a Tukey-Kramer post-hoc test); Scale
bars = 125 mm.
doi:10.1371/journal.pone.0096285.g002

Figure 1. Iron deposits are increased in lungs of COPD
subjects. Iron deposits were stained with Perls-DAB staining in lung
samples obtained from (A) a patient without COPD, (B) a patient with
GOLD 2 COPD and (C) a patient with GOLD 4 COPD. (D) Quantification
of iron positive cellular area was performed on lung sections from 8
subjects without COPD, 9 subjects with GOLD 2 or 3 COPD and 20
subjects with GOLD 4 COPD. (E) Correlation between the iron deposits
and the mean radiograph attenuation in the same lung area. *p,0.05
(Anova analysis with a Tukey-Kramer post-hoc test); Scale
bars = 125 mm.
doi:10.1371/journal.pone.0096285.g001

macrophages correlated with the mean radiograph attenuation of
the lung tissue sample (Fig. 2E). These data suggest that the
percentage of iron-positive macrophage increases with the severity
of COPD and emphysema.

receptor between GOLD 4 COPD lungs and non-COPD lungs
(Fig. 3B).
To determine which cells in the lungs expressed transferrin and
whether the expression of transferrin was associated with iron
deposition, lung sections of non-COPD and GOLD 4 COPD
subjects were co-stained for Perls-DAB and transferrin. NonCOPD lungs showed scant staining for transferrin, localized
mainly to alveolar macrophages based on location and cell
morphology (Fig. 3C). However, in GOLD 4 COPD lungs, the
majority of the transferrin-positive cells were parenchymal cells,
and not the iron-positive alveolar macrophages (Fig. 3D).
Together, these data suggest that iron-uptake gene expression is
increased in severe COPD lungs compared to non-COPD lungs,
but the iron-binding protein transferrin is not expressed by the
macrophages which accumulate the iron.

Increased Expression of Iron Uptake Genes in COPD
Lungs
Iron metabolism needs to be tightly regulated due to potential
harmful effects of excess free iron. Free iron is bound by
transferrin, taken into cells by the transferrin receptor, and is
stored in cells bound to ferritin. Iron can be exported from cells via
ferroportin. The expression of these genes is tightly regulated via
the iron-responsive proteins (IREBs), which are able to interact
with 59 or 39 untranslated region of their mRNA [16]. Among the
two orthologous, IREB 2 has been associated with airflow
limitation in GWA studies [17–19].
To determine wether the increased iron accumulation in COPD
alveolar macrophages was a result of an increase in the expression
of mRNAs encoding iron uptake proteins, we assessed the
expression of transferrin and the transferrin receptor by real-time
RT-PCR using RNA from 8 non-COPD lungsamples and 16
GOLD 4 COPD lungsamples. Transferrin expression was
significantly increased in GOLD 4 COPD lungs compared to
non-COPD lungs (fold increase = 6.9, p = 5.461026, Fig. 3A).
There was no significant difference in the expression of transferrin

PLOS ONE | www.plosone.org

Expression of Iron Retention and Homeostasis Genes in
COPD Lungs
Net iron accumulation could also be caused by an increase in
cellular iron retention and/or a decrease in iron export.
Accordingly, we examined the expression of genes related to iron
retention and export, ferritin and ferroportin, respectively, by realtime RT-PCR using RNA from 8 non-COPD lung samples and
16 GOLD 4 COPD lung samples. Ferritin mRNA expression was
significantly increased in GOLD 4 COPD lungs compared to non4
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Figure 3. Iron uptake capacities are altered in lungs of COPD subjects. mRNA expression of (A) transferrin and (B) transferrin receptor was
investigated in whole-lung total RNA samples obtained from 8 subjects without COPD and 16 subjects with GOLD 4 COPD. Three reference genes
(GAPDH, HPRT1 and PPIA) were used for normalization. Costaining for transferrin and iron deposits, by Perls-DAB staining, was performed on lung
samples obtained from (C) a subject without COPD and (D) a subject with GOLD 4 COPD. *p,0.05 (Student’s t test), Scale bars = 125 mm.
doi:10.1371/journal.pone.0096285.g003

COPD lungs (fold increase = 3.22, p = 0.031, Fig. 4A), while the
expression of ferroportin mRNA was unchanged (Fig. 4D).
Consistent with the increased intracellular retention of iron in
macrophages in COPD lungs, increased ferritin staining in COPD
lungs (Fig. 4B) compared to non-COPD lungs (Fig. 4C) localized
to alveolar macrophages. IREB2 mRNA expression was signifcantly higher in GOLD4-COPD than in non-COPD (fold
increase = 1.6, p = 0.045, Fig. 4E).
We also looked for a correlation between the expression of these
iron metabolism related genes and the emphysema severity. We
did not find any statistically signficant correlation betwen the
expression of these genes and the mean radiograph attenuation of
the lung tissue (Table S2).
To determine whether iron deposits and ferritin were present in
the same macrophages in COPD lungs, we performed CD68/
Perls-DAB and CD68/ferritin co-staining on consecutive GOLD
4 COPD lung sections (Fig. 5). Iron-positive macrophages
exhibited strong ferritin staining (arrows). Inversely, iron-negative
macrophages did not have any ferritin staining (within circle).
These data suggest that the iron accumulation in alveolar
macrophages in severe COPD lungs may, at least in part, be due
to an increase in cellular iron retention mechanisms.

from these studies may largely reflect gene expression by
macrophages.
Compared to non-smokers, transferrin expression by BAL cells
from non-COPD smokers and COPD subjects was significantly
decreased (fold increase = 0.52 and 0.13 repectively,
p = 5.761024, Fig. 6A). In contrast, the transferrin receptor was
more highly expressed in BAL cells from COPD subjects
compared to non-smokers or non-COPD smokers (fold increase = 11 or 14 respectively, p = 6.761023, Fig. 6B). When
investigating mechanisms of iron retention, we found a significantly higher expression of ferritin by BAL cells from COPD
subjects compared to non-smokers (fold increase = 23, p = 0.028,
Fig. 6C). Interestingly, whereas ferroportin expression appeared to
be similar between BAL cells from non-smokers and COPD
subjects, its expression was significantly higher in BAL cells from
non-COPD smokers than in the COPDsubjects (fold increase = 7.5, p = 0.028, Fig. 6D). IREB2 expression did not differ
between the COPD and the other groups (Fig. 6E). These data
support those presented above and show that the expression of
iron metabolism genes is altered in alveolar macrophages from
COPD patients compared to non-COPD patients which could
result in the increased iron accumulation.

Expression of Iron Metabolism Genes in GOLD 1–3 COPD
BAL Cells

Iron Metabolism Gene Expression in BAL Cells Correlates
with Airflow Limitation

The data presented in Figures 3 and 4 were obtained using
mRNA from whole lung tissue samples. To better understand iron
accumulationin alveolar macrophages of severe COPD lungs, we
investigated the expression of iron metabolism genes in BAL cells
(Fig. 6). By cytological analysis, nearly 90% of cells in the BAL
fluid were macrophages (Table 2). Therefore, the data obtained

Next, we investigated correlations between expression of genes
related to iron metabolism by BAL cells and airflow limitation
indices (Fig. 7). Expression of transferrin positively correlated with
both FEV1and the ratio FEV1/FVC (Fig. 7 A and F). Inversely,
expression of the transferrin receptor and ferritin negatively
correlated with airflow limitation (Fig. 7 B–G and C–H). Finally,
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Figure 4. Iron storage capacities are altered in lungs of COPD subjects. mRNA expression of (A) ferritin, (D) ferroportin and (E) IREB2 was
investigated in whole-lung total RNA samples obtained from 8 subjects without COPD and 16 subjects with GOLD 4 COPD.Three reference genes
(GAPDH, HPRT1 and PPIA) were used for normalization. Immunohistochemistry study of ferritin, with nuclear fast red counterstaining, in lung samples
obtained from (B) a subject without COPD and (C) a subject with GOLD 4 COPD. *p,0.05 (Student’s t test), Scale bars = 125 mm.
doi:10.1371/journal.pone.0096285.g004

the expression of ferroportin and IREB2 did not significantly
correlate with the airflow limitation. Interestingly, expression of
these iron related genes did not correlate with hemoglobin or CRP
serum concentration. IREB2 expression only correlated with
subject age (Table S3). Similarly, expression of studied iron related

genes was not influenced by the subject sex or the presence of
chronic bronchitis (Table S4). The expression of some iron
metabolism related genes were associated with dyspnea severity
(transferrin), exacerbation rate (transferrin and ferritin) (Table S4)
and smoking history including smoking pack-year (transferrin and
ferritin) (Table S3) and smoking status (transferrin, ferritin and
ferroportin) (Table S5). Finally, in the COPD patients, no relation
was found between the presence of an inhaled treatment and the
expression of iron metabolism related genes (data not shown).
Globally, these data demonstrate that changes in macrophage
expression of iron metabolism genes correlate with airflow
limitation and COPD severity.

Discussion
The main findings of this study are that: 1) iron deposits are
localized in macrophages in COPD lungs; 2) the quantity of lung
iron deposits increases with COPD and emphysema severity; 3)
expression of transferrin (involved in iron uptake), and of ferritin
(involved in iron storage), are increased in severe COPD lungs
whereas ferroportin (involved in cellular excretion of iron) is
unchanged; 4) in BAL cells from COPD subjects at GOLD stage
1–3, expression of transferrin receptor and ferritin expression are
increased, and 5) indices of airflow limitation correlate with
expression of transferrin, transferrin receptor and ferritin in BAL
cells from healthy non smokers and smokers, and COPD subjects.
Consistent with our results, iron accumulation has been
reported in the lungs of cigarette smokers [4–6] and in severe
emphysema [7] but the mechanisms sustaining the iron accumulation in lungs from COPD patients have never been explored.
Iron uptake, storage and sequestration are of interest in COPD.
Indeed in other diseases associated with aging, including

Figure 5. Iron deposits and ferritin staining are colocalized in
the same subset of macrophages (A) Costaining for ferritin and
CD68 and (A’) with Perls-DAB and CD68 in two adjacent lung
sections from a GOLD 4 COPD patient. The arrows show iron and
ferritin positive macrophages, inside circles are iron and ferritin
negative macrophages. Scale bars = 125 mm.
doi:10.1371/journal.pone.0096285.g005
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Figure 6. Expression of proteins involved in iron metabolism is altered in BAL cells obtained in subjects with COPD. Expression of
proteins involved in iron metabolism in BAL cells collected in 8 non smokers without COPD, 8 smokers without COPD and 10 GOLD 1–3 COPD
subjects was examined by RT-PCR.Three reference genes (GAPDH, HPRT1 and PPIA) were used for normalization. *p,0.05 (Anova analysis with a
Tukey-Kramer post-hoc test), NS: non smokers.
doi:10.1371/journal.pone.0096285.g006

atherosclerosis, Parkinson’s and Alzheimer’s, iron depositions are
postulated to contribute to excess oxidative stress [2], which is now
recognized as important in the pathogenesis of COPD [20,21].

Moreover, free iron acumulation in the lung may promote
bacterial growth and influence COPD exacerbation. Therefore,

Figure 7. In BAL cells, expression of proteins involved in iron metabolism correlate with airflow limitation. (A–J) Correlation between
the expression of genes encoding proteins involved in iron metabolism in BAL cells, as determined by RT-PCR, and airflow limitation was assessed in 8
non smokers without COPD, 8 smokers without COPD and 10 GOLD 1–3 COPD subjects.Three reference genes (GAPDH, HPRT1 and PPIA) were used
for normalization. (Spearman rank correlation).
doi:10.1371/journal.pone.0096285.g007
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the free iron pool has to be tightly controlled to protect the lung
against the harmful properties of iron.
Iron bound by transferrin is taken up into cells by the transferrin
receptor, and is stored in cells bound to ferritin. Compared to
control lungs, higher transferrin and ferritin expression was found
in COPD lungs, and transferrin receptor was higher in BAL from
COPD subjects than in healthy subjects. Further, the expression of
ferroportin, the only known iron exporter, was unchanged with
COPD. These findings support active iron sequestration by
alveolar macrophages in COPD lungs, and may represent a
protective maneuver intended to control free iron, and therefore,
perverse effects of iron. In fact, O. Olakanmi et al have reported
that iron sequestration by alveolar macrophages decresease the
formation of the highly toxic hydroxyl radical [22] and more
recently, it has been shown that iron sequestration by macrophages protects A549 cells against iron toxicity [23]. Consistent
with these resluts, we did not find a spatial relationship between
the accumulation of 8-hydroxyguanosine, a marker of nucleic
acids oxidation, and iron staining in COPD lung specimens in this
study (data not shown). While not conclusive, this suggests at least
that iron accumulation process in alveolar macrophages does not
contribute locally to increased oxidative stress and may even
decrease iron induced oxidative stress. Interestingly, current
cigarette smoke exposure was not found necessary to alter iron
metabolism. Indeed, GOLD 4 COPD subjects in this study had
ceased cigarette smoking for at least 6 months prior to transplant
and processing of their lung tissue.
The clinical relevance of these findings is supported by the
correlations between expression levels of several iron pathway
mRNAs in BAL cells and indices of airflow limitation in this study.
Ferritin and transferrin receptor expression were increased in
COPD subjects and correlated with a decrease in FEV1 or FEV1/
FVC ratio. IREB2 expression tended to be higher in BAL of
COPD subjects and correlated negatively with FEV1/FVC ratio,
supporting a shift in iron metabolism in macrophages in COPD.
These studies were limited to smokers, former smokers, and
GOLD 2 and -3 COPD subjects, as there is high risk in obtaining
BAL from GOLD 4 COPD subjects. Another aspect of the study
which may be a limitation is that distinct study sets were employed
for the tissue-based and BAL-based experiments. Alternatively,
that iron metabolism was altered in separate cohorts of subjects
may lend greater weight to the findings. Altering lung iron uptake
in macrophages during cigarette smoke exposure in animal model
could be employed to test whether this impacts overall lung
oxidative stress and the progression of alveolar enlargement. In
vitro studies in macrophages could further test the relationships
between cigarette smoke exposure, free iron, iron sequestration,
ROS generation and oxidative stress.

Overall this study demonstrates that macrophages in the lungs
of COPD subjects have increased iron uptake and storage, likely
through increased expression of transferrin, transferrin receptor
and ferritin, while ferroportin expression is unchanged. This
should result in a net gain in iron sequestration in COPD lung
macrophages, which we postulate is a protective mechanism
intended to reduce free iron and its harmful effects. Similar to the
robust anti-oxiodant response reported in COPD lungs [21], it
seems likely that iron sequestration may be a mechanism that is
intended to limit, but fails to eliminate, progression of COPD.
Further investigations are needed to elucidate the contribution of
iron sequestration in alveolar macrophages in the complex
pathophysiology of COPD.

Supporting Information
Table S1 Sequence of primer pairs used in our RT-PCR

reactions.
(DOCX)
Table S2 Lack of relationship between subject lung density in
CT Hounsfield units and iron metabolism gene expression.
(DOCX)
Table S3 Relationships between expression of iron metabolismrelated mRNAs age, smoking pack years, and KCO, but not
serum variables.
(DOCX)
Table S4 Lack of relationship between expression of iron

metabolism-related mRNAs and subject gender, dyspnea. Transferrin correlate with the presence of chronic bronchitis. Transferrin and ferritin are correlated with the presence of exacerbations.
(DOCX)
Table S5 Expression of transferrin, ferritin and IREB2 are

impacted by smoking status.
(DOCX)

Acknowledgments
This work was supported by NIH P50HL084922 (J.C.W., D.D., M.J.H.,
R.A.P.), the Alafi Neuroimaging Laboratory, the Hope Center for
Neurological Disorders, and NIH Neuroscience Blueprint Center Core
Grant P30 NS057105 to Washington University.

Author Contributions
Performed the experiments: QP TAK. Analyzed the data: QP GD TAK
RAP. Contributed reagents/materials/analysis tools: GD JCW DB SC SD
FL CC RLN JMP RAP. Wrote the paper: QP GD TAK MJH RAP.

References
1. Jomova K, Valko M (2011) Advances in metal-induced oxidative stress and
human disease. Toxicology 283: 65–87. doi:10.1016/j.tox.2011.03.001.
2. Altamura S, Muckenthaler MU (2009) Iron Toxicity in Diseases of Aging:
Alzheimer’s Disease, Parkinson’s Disease and Atherosclerosis. J Alzheimers Dis
16: 879–895. doi:10.3233/JAD-2009-1010.
3. Vestbo J, Hurd SS, Agustı́ AG, Jones PW, Vogelmeier C, et al. (2013) Global
Strategy for the Diagnosis, Management, and Prevention of Chronic
Obstructive Pulmonary Disease. Am J Respir Crit Care Med 187: 347–365.
doi:10.1164/rccm.201204-0596PP.
4. Thompson AB, Bohling T, Heires A, Linder J, Rennard SI (1991) Lower
respiratory tract iron burden is increased in association with cigarette smoking.
J Lab Clin Med 117: 493–499.
5. Nelson ME, O’Brien-Ladner AR, Wesselius LJ (1996) Regional variation in iron
and iron-binding proteins within the lungs of smokers. Am J Respir Crit Care
Med 153: 1353–1358. doi:10.1164/ajrccm.153.4.8616566.
6. Wesselius LJ, Nelson ME, Skikne BS (1994) Increased release of ferritin and iron
by iron-loaded alveolar macrophages in cigarette smokers. Am J Respir Crit
Care Med 150: 690–695. doi:10.1164/ajrccm.150.3.8087339.

PLOS ONE | www.plosone.org

7. Takemoto K, Kawai H, Kuwahara T, Nishina M, Adachi S (1991) Metal
concentrations in human lung tissue, with special reference to age, sex, cause of
death, emphysema and contamination of lung tissue. Int Arch Occup Environ
Health 62: 579–586.
8. Ghio AJ, Hilborn ED, Stonehuerner JG, Dailey LA, Carter JD, et al. (2008)
Particulate Matter in Cigarette Smoke Alters Iron Homeostasis to Produce a
Biological Effect. Am J Respir Crit Care Med 178: 1130–1138. doi:10.1164/
rccm.200802-334OC.
9. Deslee G, Woods JC, Moore C, Conradi SH, Gierada DS, et al. (2009)
OXidative damage to nucleic acids in severe emphysema. CHEST J 135: 965–
974. doi:10.1378/chest.08-2257.
10. Workshop summary and guidelines: Investigative use of bronchoscopy, lavage,
and bronchial biopsies in asthma and other airway diseases (1991). J Allergy Clin
Immunol 88: 808–814. doi:10.1016/0091-6749(91)90189-U.
11. Tanino M, Betsuyaku T, Takeyabu K, Tanino Y, Yamaguchi E, et al. (2002)
Increased levels of interleukin-8 in BAL fluid from smokers susceptible to
pulmonary emphysema. Thorax 57: 405–411. doi:10.1136/thorax.57.5.405.

8

May 2014 | Volume 9 | Issue 5 | e96285

Iron in COPD

18. Kim WJ, Wood AM, Barker AF, Brantly ML, Campbell EJ, et al. (2012)
Association of IREB2 and CHRNA3 polymorphisms with airflow obstruction in
severe alpha-1 antitrypsin deficiency. Respir Res 13: 16. doi:10.1186/14659921-13-16.
19. DeMeo DL, Mariani T, Bhattacharya S, Srisuma S, Lange C, et al. (2009)
Integration of Genomic and Genetic Approaches Implicates IREB2 as a COPD
Susceptibility Gene. Am J Hum Genet 85: 493–502. doi:10.1016/
j.ajhg.2009.09.004.
20. Barnes PJ, Shapiro SD, Pauwels RA (2003) Chronic obstructive pulmonary
disease: molecular and cellularmechanisms. Eur Respir J 22: 672–688.
doi:10.1183/09031936.03.00040703.
21. Rahman I (2005) Oxidative stress in pathogenesis of chronic obstructive
pulmonary disease. Cell Biochem Biophys 43: 167–188. doi:10.1385/CBB:43: 1:
167.
22. Olakanmi O, McGowan SE, Hayek MB, Britigan BE (1993) Iron sequestration
by macrophages decreases the potential for extracellular hydroxyl radical
formation. J Clin Invest 91: 889–899. doi:10.1172/JCI116310.
23. Persson HL, Vainikka LK, Eriksson I, Wennerström U (2013) TNF-a-stimulated
macrophages protect A549 lung cells against iron and oxidation. Exp Toxicol
Pathol 65: 81–89. doi:10.1016/j.etp.2011.06.004.

12. Hattotuwa K, Gamble EA, O’Shaughnessy T, Jeffery PK, Barnes NC (2002)
SAfety of bronchoscopy, biopsy, and bal in research patients with copd*.
CHEST J 122: 1909–1912. doi:10.1378/chest.122.6.1909.
13. Livak KJ, Schmittgen TD (2001) Analysis of Relative Gene Expression Data
Using Real-Time Quantitative PCR and the 22DDCT Method. Methods 25:
402–408. doi:10.1006/meth.2001.1262.
14. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, et al. (2002)
Accurate normalization of real-time quantitative RT-PCR data by geometric
averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.
15. Glynos C, Dupont LL, Vassilakopoulos T, Papapetropoulos A, Brouckaert P, et
al. (2013) The role of soluble guanylyl cyclase in chronic obstructive pulmonary
disease. Am J Respir Crit Care Med 188: 789–799. doi:10.1164/rccm.2012101884OC.
16. Wang J, Pantopoulos K (2011) Regulation of cellular iron metabolism. Biochem J
434: 365–381. doi:10.1042/BJ20101825.
17. Hardin M, Zielinski J, Wan ES, Hersh CP, Castaldi PJ, et al. (2012) CHRNA3/
5, IREB2, and ADCY2 Are Associated with Severe Chronic Obstructive
Pulmonary Disease in Poland. Am J Respir Cell Mol Biol 47: 203–208.
doi:10.1165/rcmb.2012-0011OC.

PLOS ONE | www.plosone.org

9

May 2014 | Volume 9 | Issue 5 | e96285

